News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Nord Investimentos Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Eupraxia Pharmaceuticals Inc. announced positive results from an analysis of its RESOLVE study, showing significant symptom improvements in eosinophilic esophagitis (EoE) patients treated with EP-104GI. The analysis revealed a substantial decrease in moderate to severe odynophagia and dysphagia, with severe symptoms dropping to zero …
Eupraxia Pharmaceuticals announced positive symptom response data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis showed significant reductions in moderate to severe odynophagia (pain swallowing) and dysphagia (difficulty swallowing) lasting up to 52 weeks post-treatment, with no …
This article provides a detailed overview of Eupraxia Pharmaceuticals, Inc. (EPRX) stock on the Toronto Stock Exchange, including its current price, historical performance, key financial statistics, and analyst ratings. It highlights the company's focus on drug delivery technology for conditions like arthritis and chronic …
Eupraxia Pharmaceuticals Inc. reported Q2 2026 EPS of $(0.23), surpassing analyst estimates of $(0.25) despite a wider net loss of $14.5 million, primarily due to increased R&D spending for its lead EoE asset, EP-104GI. The company maintains strong liquidity with $133.6 million in cash …
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported a quarterly loss of $0.23 per share, surpassing analyst estimates by $0.02. Shares saw a modest increase of 0.6% to $6.70, and the company maintains strong financial liquidity. Analyst sentiment for EPRX is mixed but generally positive, with a "Moderate …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%Eupraxia Pharmaceuticals reported a widened net loss of $27.1 million for the six months ended June 30, 2026, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its liquidity by raising $58.6 million …
AXIA Energia (BVMF:AXIA3) has shown impressive profit growth, with earnings per share skyrocketing 44% in the last year, alongside improved EBIT margins. The company also benefits from significant insider ownership, indicating strong commitment from management. These factors suggest AXIA Energia could be a promising …
AXIA Energia S.A. has announced that its American Depositary Receipts (ADRs) have begun trading on the U.S. over-the-counter (OTC) market under ticker symbols AXIAY for common shares and AXICY for Class C preferred shares. Concurrently, the company filed Form 15F with the SEC to …
This article provides an earnings forecast for Eupraxia Pharmaceuticals Inc (EPRX), highlighting analyst ratings, target prices, and historical/projected EPS and revenue growth. Nine analysts currently rate EPRX as a "Buy" with a target price of USD 16.444, suggesting a 146.91% upside. The article also …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%This article provides current stock information for Eupraxia Pharmaceuticals Inc (EPRX), showing its stock price, market capitalization, and a brief overview of available financial data sections on the TradingKey platform. It indicates that more news regarding EPRX is expected soon. The content primarily serves …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%AXIA Energia reported a 21.5% increase in adjusted regulatory EBITDA to R$ 6,683 million for Q2 2026, driven by stronger generation margins and significant investments in transmission and modernization. Despite beating earnings expectations, revenue fell slightly short of estimates, leading to a measured market …
AXIA Energia reported strong Q2 2026 results with adjusted regulatory EBITDA surging 21.5% year-over-year to R$ 6,683 million, primarily due to improved generation margins and cost management. The Brazilian utility also significantly increased its investments by 52.6% to R$ 3,117 million, focusing on transmission …
Eupraxia Pharmaceuticals Inc. has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 in mixed securities, including common shares, preferred shares, debt securities, warrants, subscription receipts, and units. These securities may be offered over a 25-month period …
AXIA Energia (AXIA) reported strong financial results for Q2 2026, with Adjusted Regulatory EBITDA increasing by 21.5% year-over-year to R$ 6,683 million and IFRS net income turning from a loss to a R$ 1,191 million profit. The company significantly expanded its transmission investments, securing …
AXIA Energia reported mixed Q2 2026 results, beating profit expectations with EPS of $0.1974 against a forecast of $0.1867, but missing revenue estimates at $2.02 billion versus $2.06 billion. The company attributes its strong profitability to improved generation margins and disciplined cost control, despite …
AXIA Energia S.A. (AXIA) announced the redemption of its class "C" preferred shares (PNC) at R$ 53.71 per share, based on the August 5, 2026 common share closing price. The record date for redemption is August 7, 2026, with payment to be made on …
AXIA Energia S.A. has approved a second redemption/conversion operation for its Class C Preferred Shares (PNC), authorizing the redemption of 37,237,014 PNC shares, equivalent to R$2.0 billion. This represents 6.14% of the outstanding shares of this class, with the redemption value set at R$53.71 …
Search by ticker symbol or company name and select a result to open its chart.